^
Association details:
| Biomarker: | ETV6-NTRK3 fusion |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Augtyro (repotrectinib) (ALK inhibitor, Multi-tyrosine kinase inhibitor, ROS1 inhibitor, Trk inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TPX-0005 (Repotrectinib), a next-generation ALK/ROS1/NTRK1-3 inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models
Published date:
10/09/2020
Excerpt:
TPX-0005 also induced a near complete response (>80% tumor volume reduction) after four weeks of treatment in a PDX model characterized by ETV6-NTRK3 fusion harboring a known solvent front mutation.
